Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.
Also called NCT06076824
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Hospital General Universitario de Alicante
- Registry
-
NCT06076824
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Spain
- Registry status
- Unknown status
Technical summary
Registry record NCT06076824. Randomized; single masking; primary purpose prevention. Start 2023-08-12 (actual); primary completion 2024-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glucocorticoid Treatment in Transaortic Valve Replacement to Reduce the Incidence of Conduction Disturbances (GLUCO-TAVR).
- Acronym
- GLUCO-TAVR
- Condition
- Heart Block
- Condition
- Aortic Stenosis
- Condition
- Bundle-Branch Block
- Intervention (Drug)
- Methylprednisolone
- Intervention (Other)
- Placebo
- Lead sponsor
- Hospital General Universitario de Alicante
Record details
- Record id
cardio:ct-nct06076824- Content hash
c0505de731589130409b65445d829bc73b4fe354bf2179cd35302d09f23ac817